Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

about

Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.

P2860

Q30978290-95D241DF-B5D0-484F-A485-0C6D3D46D078 Q38731776-41F6CFA6-F790-4E5A-98DD-B12C147EAC54 Q38865133-532FE2B7-BBB0-4276-8BA1-335156B7A9FE

P2860

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

Item

http://www.wikidata.org/entity/Q38075827

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

@en

type

Item

label

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

@en

prefLabel

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

@en

P1476

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

@en

P2093

Anne Demols

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Van Laethem

http://www.w3.org/2001/XMLSchema#string

Raphaël Maréchal

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Cancer statistics, 2008

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

Cancer statistics, 2006

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study.

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

P2888

s40266-013-0049-0

P304

155-165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40266-013-0049-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23338795

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

about

P2860

P2860

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921